Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI8897 (nirsevimab) in healthy preterm infants
NCT02878330Phase 2Completed
- Sponsor
- MedImmune
- Start
- Nov 2016
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 2 trial of nirsevimab in respiratory syncytial virus infection (RSV), sponsored by MedImmune. Started Nov 2016; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02878330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878330.